Eficacia en términos de respuesta clínica según criterios RECIST del tratamiento de primera línea con capecitabina en monoterapia en una paciente con carcinoma epidermoide de vagina y metástasis pulmonares

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Los datos en la literatura acerca del tratamiento de quimioterapia en carcinoma escamoso metastásico vaginal son escasos y a menudo incompletos, debido a la escasa incidencia de este tipo de tumores. Además, algunos pacientes valorados en la práctica clínica, habitualmente no son buenos candidatos para tratamientos estándar o ensayos clínicos. En estos casos los nuevos tratamientos pueden ser una buena opción, cuando los pacientes no cumplen los criterios de selección para los ensayos clínicos. Se presenta un caso clínico de una paciente con un carcinoma vaginal y metástasis pulmonares que obtuvo una respuesta parcial (según criterios RECIST) tras tres ciclos de capecitabina en monoterapia.

Translated abstract

Literature data about chemotherapy of vaginal metastatic squamous cell carcinoma are limited because of the rare incidence of this kind of tumours. In addition, some patients evaluated in clinical practice, usually are not good candidates for standard treatments or clinical trials. This situation makes new treatments a good choice, unless patients meet the selection criteria to be included in a clinical trial. We present a case of lung metastatic vaginal carcinoma with partial response (RECIST criteria) after three cycles of capecitabine monotherapy.

Related collections

Most cited references 11

Record: found
Abstract: found
Article: not found

Factors affecting long-term outcome of irradiation in carcinoma of the vagina.

D G Mutch, Michelle Lockett, M Garipagaoglu … (1999)

This report evaluates prognostic and technical factors affecting outcome of patients with primary carcinoma of the vagina treated with definitive radiation therapy. A retrospective analysis was performed on records of 212 patients with histologically confirmed carcinoma of the vagina treated with irradiation. Tumor stage was the most significant prognostic factor; actuarial 10-year disease-free survival was 94% for Stage 0 (20 patients), 80% for Stage I (59 patients), 55% for Stage IIA (63 patients), 35% for Stage IIB (34 patients), 38% for Stage III (20 patients), and 0% for Stage IV (15 patients). All in situ lesions except one were controlled with intracavitary therapy. Of the patients with Stage I disease, 86% showed no evidence of vaginal or pelvic recurrence; most of them received interstitial or intracavitary therapy or both, and the addition of external-beam irradiation did not significantly increase survival or tumor control. In Stage IIA (paravaginal extension) and IIB (parametrial involvement) 66% and 56% of the tumors, respectively, were controlled with a combination of brachytherapy and external-beam irradiation; 13 of 20 (65%) Stage III tumors were controlled in the pelvis. Four patients with Stage IV disease (27%) had no recurrence in the pelvis. The total incidence of distant metastases was 13% in Stage I, 30% in Stage IIA, 52% in Stage IIB, 50% in Stage III, and 47% in Stage IV. The dose of irradiation delivered to the primary tumor or the parametrial extension was of relative importance in achieving successful results. In patients with Stage I disease, brachytherapy alone achieved the same local tumor control (80-100%) as in patients receiving external pelvic irradiation (78-100%) as well. In Stage II and III there was a trend toward better tumor control (57-80%) with combined external irradiation and brachytherapy than with the latter alone (33-50%) (p = 0.42). The incidence of grade 2-3 complications (12%) correlated with the stage of the tumor and type of treatment given. Radiation therapy is an effective treatment for patients with vaginal carcinoma, particularly Stage I. More effective irradiation techniques, including optimization of dose distribution combining external irradiation and interstitial brachytherapy in tumors beyond Stage I, are necessary to enhance locoregional tumor control. The high incidence of distant metastases emphasizes the need for earlier diagnosis and effective systemic cytotoxic agents to improve survival in these patients.

0 comments Cited 15 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Carcinoma of the vagina--experience at the Princess Margaret Hospital (1974-1989).

J Simm, Kenneth Kirkbride, Nigel Rawlings … (1995)

The charts of 153 patients with vaginal carcinoma or carcinoma in situ seen at Princess Margaret Hospital between 1974 and 1989 were analyzed with respect to treatment modality, radiation dose and technique, complications, and survival. One hundred and twenty-eight patients were treated with radiation therapy, of which 10 received radiation postoperatively and 26 concomitant chemotherapy. The overall 5-year actuarial cause-specific survival was 66%. The 5-year cause-specific survivals by stage were Stage 0 (C-I-S) 100%, Stages I/II 77%, and Stages III/IV 56%. Late complications from treatment were infrequent and in only 12 patients were such complications classified as severe. Univariate analysis indicated that size and stage of tumor, histological grade, patient age, and radiation dose > 7000 cGy were significant factors in predicting survival, although in a multivariate analysis only size and stage retained significance. Fifty-one patients had a prior gynecological malignancy arising 1-37 years previously, of which 34 had cervical cancers. Radiotherapy is an effective treatment for all stages of carcinoma of the vagina and doses of at least 7000 cGy are recommended to maximize tumor control.

0 comments Cited 14 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix.

C. Sun, Gregory D. Jenkins, Stuart Johnston … (2005)

To determine the efficacy and safety of capecitabine in women with inoperable, recurrent, or metastatic squamous cell cervical cancer. In a phase II IRB approved trial, capecitabine was given at a dosage of 2000 mg/m2/day orally in a divided dose daily for 14 days followed by a 7-day rest period. A standard dose modification scheme was used with one allowed dose reduction or dose escalation. National Cancer Institute criteria for progression, response, and toxicity were utilized. Quality of life data were obtained using the Memorial Symptom Assessment Scale and Functional Assessment for Cancer Therapy, which included a subscale for cervical cancer. Twenty of 23 enrolled patients were evaluable for response. Stable disease was noted in 5 patients, with a median duration of response of 3.5 months (range, 3-6.5 months). No partial or complete responses were seen. Common grade 3 toxicities were fatigue (30.4%); abdominal pain, constipation, hand-foot syndrome, nausea, and vomiting (8.7% each); as well as dyspnea, headache, and coagulopathy (4.3% each). There were no grade 4 toxicities. All patients with previous exposure to infused 5-FU had evidence of progression. No statistically significant changes in quality of life were noted from baseline to post-cycle 2. Single-agent capecitabine in patients with recurrent cervical cancer resulted in no objective responses. Although capecitabine is a well-tolerated regimen, as a single agent, it offers minimal benefit in a poor-prognosis cervical cancer population.

0 comments Cited 3 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

D. Gutiérrez Abad: Role: ND

A. Casado Herráez: Role: ND

E. Filipovich Vegas: Role: ND

G. Hernández Muro: Role: ND

Journal

Journal ID (publisher-id): onco

Title: Oncología (Barcelona)

Abbreviated Title: Oncología (Barc.)

Publisher: Alpe Editores, S.A. (, , Spain )

ISSN (Print): 0378-4835

Publication date (Print and electronic): December 2006

Volume: 29

Issue: 10

Pages: 37-39

Affiliations

[02] orgnameHospital Nuestra Señora de Sonsoles orgdiv1Unidad de Oncología Médica

[01] Madrid orgnameHospital Clínico San Carlos orgdiv1Servicio de Oncología Médica

[03] Ávila orgnameHospital Nuestra Señora de Sonsoles orgdiv1Servicio de Radiología

Article

Publisher ID: S0378-48352006001000006

DOI: 10.4321/s0378-48352006001000006

SO-VID: af232d65-a11a-410e-9d77-a917bd71d721

License:

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 International License.

History

Date accepted : 19 September 2006

Date received : 09 June 2006

Date revision received : 05 September 2006

Page count

Figures: 0, Tables: 0, Equations: 0, References: 8, Pages: 3

Product

SciELO Spain

Keywords: Carcinoma escamoso vaginal,Metástasis pulmonares,Capecitabina,Squamous cell vaginal carcinoma,Lung metastases,Capecitabine

Data availability:

Keywords: Carcinoma escamoso vaginal, Metástasis pulmonares, Capecitabina, Squamous cell vaginal carcinoma, Lung metastases, Capecitabine

Read this article at

Abstract

Translated abstract

Related collections

SciELO Spain

Most cited references 11

Factors affecting long-term outcome of irradiation in carcinoma of the vagina.

Carcinoma of the vagina--experience at the Princess Margaret Hospital (1974-1989).

Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix.

Author and article information

Contributors

Journal

Affiliations

Article

History

Page count

Product

Comments

Comment on this article

Similar content 449

Most referenced authors 85